A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years

PHASE2CompletedINTERVENTIONAL
Enrollment

175

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Lymphoma
Interventions
BIOLOGICAL

bleomycin sulfate

Treatment

DRUG

cyclophosphamide

Treatment

DRUG

etoposide

Treatment

DRUG

mitoxantrone hydrochloride

Treatment

DRUG

prednisolone

Treatment

DRUG

procarbazine hydrochloride

Treatment

DRUG

vinblastine sulfate

Treatment

Trial Locations (54)

D-50924

Medizinische Universitaetsklinik I at the University of Cologne, Cologne

NE63 9JJ

Wansbeck General Hospital, Ashington

RG24 9NA

Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke

BA1 3NG

Royal United Hospital, Bath

B75 7RR

Good Hope Hospital, Birmingham

FY3 8NR

Blackpool Victoria Hospital, Blackpool

BH7 7DW

Royal Bournemouth Hospital, Bournemouth

BD9 6RJ

Bradford Royal Infirmary, Bradford

CT1 3NG

Kent and Canterbury Hospital, Canterbury

CA2 7HY

Cumberland Infirmary, Carlisle

P019 4SE

Saint Richards Hospital, Chichester

DH1 5TW

University Hospital of North Durham, Durham

NE9 6SX

Queen Elizabeth Hospital, Gateshead-Tyne and Wear

ME7 5NY

Medway Maritime Hospital, Gillingham Kent

DN33 2BA

Diana Princess of Wales Hospital, Grimsby

HG2 7SX

Harrogate District Hospital, Harrogate

HU3 2KZ

Hull Royal Infirmary, Hull

IP4 5PD

Ipswich Hospital, Ipswich

BD20 6TD

Airedale General Hospital, Keighley

NNI6 8UZ

Kettering General Hosptial, Kettering, Northants

LS1 3EX

Leeds General Infirmary, Leeds

LE1 5WW

Leicester Royal Infirmary, Leicester

L7 8XP

Royal Liverpool University Hospital, Liverpool

NW1 2PG

University College Hospital - London, London

ME16 9QQ

Maidstone Hospital, Maidstone

M13 9WL

Manchester Royal Infirmary, Manchester

M20 4BX

Christie Hospital, Manchester

M31 3SL

Trafford General Hospital, Manchester

TS4 3BW

James Cook University Hospital, Middlesbrough

NE2 4HH

University of Newcastle-Upon-Tyne Northern Institute for Cancer Research, Newcastle upon Tyne

NE4 6BE

Northern Centre for Cancer Treatment at Newcastle General Hospital, Newcastle upon Tyne

NE29 8NH

North Tyneside Hospital, North Shields

NN1 5BD

Northampton General Hospital, Northampton

HA6 2RN

Mount Vernon Cancer Centre at Mount Vernon Hospital, Northwood

BH15 2JB

Dorset Cancer Centre, Poole Dorset

TN2 4QJ

Pembury Hospital, Royal Tunbridge Wells, Kent

S1O 2JF

Royal Hallamshire Hospital, Sheffield

SL2 4HL

Wexham Park Hospital, Slough, Berkshire

NE34 0PL

South Tyneside District Hospital, South Shields

SO16 6YD

Southampton General Hospital, Southampton

ST16 3SA

Staffordshire General Hospital, Stafford

ST4 6QG

University Hospital of North Staffordshire, Stoke-On-Trent Staffs

SR4 7TP

Sunderland Royal Hospital, Sunderland

TR1 3LJ

Royal Cornwall Hospital, Truro, Cornwall

CA28 8JG

West Cumberland Hospital, Whitehaven

Y031 8HE

Cancer Care Centre at York Hospital, York

AB25 2ZN

Aberdeen Royal Infirmary, Aberdeen

ML6 0JF

Monklands General Hospital, Airdrie

EH4 2XU

Edinburgh Cancer Centre at Western General Hospital, Edinburgh

G11 6NT

Western Infirmary, Glasgow

1V2 3UJ

Raigmore Hospital, Inverness

Unknown

Royal Alexandra Hospital, Paisley

ML2 0DP

Wishaw General Hospital, Wishaw

EN5 3DJ

Barnet General Hospital, Barnet, Hertfordshire

All Listed Sponsors
lead

Newcastle-upon-Tyne Hospitals NHS Trust

OTHER

NCT00079105 - A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years | Biotech Hunter | Biotech Hunter